Amivantamab
Based on 3 publication(s) in Google Scholar
Amivantamab (JNJ-61186372) is a human EGFR-MET bispecific antibody with immune anticancer activity. Amivantamab inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells.
For research use only. We do not sell to patients.
- Purity : 99.90%
- CAS No.: 2171511-58-1
- Molecular Weight:145.88 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Amivantamab
More-
Cell Proliferation/Viability Assay
All EGFR Isoforms
More
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
EGFR & c-Met
In Vitro
Amivantamab (JNJ-61186372)(0.05-1 mg/mL) results in a significant and dose-dependent decrease in the viability of Ba/F3 cells, as well as a significant decrease in phosphorylated EGFR (pEGFR), phosphorylated AKT (pAKT), phosphorylated ERK (pERK) and phosphorylated S6 (pS6) of the EGFR downstream signaling pathway[2].
Amivantamab (JNJ-61186372) has potent antitumor activity in NSCLC patient-derived cancer cells with EGFR Exon20ins mutations through downregulation of EGFR and MET signaling pathways[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Human c-MET/HGFR Protein (ECD, His Tag) can bind Amivantamab. The EC50 for this effect is 1.20 ng/mL. -
Immobilized Human EGFR Protein can bind Amivantamab. The EC50 for this effect is 2.58 ng/mL.
Chemical Information
-
CAS No. 2171511-58-1
-
Appearance Liquid
-
Molecular Weight 145.88 kDa
-
Color Colorless to light yellow
-
SMILES
[Amivantamab]
-
Synonyms
JNJ-61186372
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Cancer Res
2025 Oct 9. PMID: 41066595 -
J Exp Clin Cancer Res
2023 Nov 4;42(1):292. PMID: 37924112
Amivantamab purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2023 Nov 4;42(1):292. [Abstract]
(A) MDA-MB-231 and (B) BT549 cells were treated with various concentrations of Amivantamab (1–1000 μg/ml) or control vehicle (DMSO) for 72 h.
-
Clin Cancer Res
STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20-Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer Models. [Abstract]2025 Jun 4:OF1-OF17. PMID: 40465424
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Keunchil Park, et al. Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. J Clin Oncol. 2021 Oct 20;39(30):3391-3402. [Content Brief]
[2]. Jiyeon Yun, et al. Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020 Aug;10(8):1194-1209. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)